Bluejay Diagnostics announces abstract acceptance at 2025 SAEM meeting

Bluejay Diagnostics (BJDX) announced acceptance of an abstract related to the Symphony IL-6 Test, the company’s lead product candidate, for presentation at the Society of Academic Emergency Medicine, SAEM, Annual Meeting, taking place in Philadelphia May 13-16, 2025. Results from SYMON-I, a pilot clinical study of interleukin-6 in sepsis patients intended or admitted for the intensive care unit, will be presented. SYMON-I evaluated IL-6 as a prognosticator for 28-day mortality and exploratory endpoints including 7-day mortality and microbiological positivity.